Streetbeat News

Price Targets

BL

Citigroup analyst Steven Enders maintains a Neutral rating on BlackLine (NASDAQ:BL) and lowers the price target from $63 to $57.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:21 pm

CE

Citigroup analyst Patrick Cunningham maintains a Neutral rating on Celanese (NYSE:CE) and raises the price target from $123 to $130.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:19 pm

EXP

Citigroup analyst Anthony Pettinari maintains a Buy rating on Eagle Materials (NYSE:EXP) and raises the price target from $215 to $219.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:18 pm

FLYW

Citigroup analyst Ashwin Shirvaikar maintains a Buy rating on Flywire (NASDAQ:FLYW) and raises the price target from $40 to $43.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:15 pm

LTRN

Zacks Small-Cap Research has set a price valuation of $26 for Lantern Pharma. The valuation could potentially influence the stock price of Lantern Pharma in the short term.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 4:15 pm

ARWR

Zacks Small-Cap Research has set a price valuation of $80 for Arrowhead Pharmaceuticals. The valuation model is highly dependent on the continued clinical success of the company's programs and will be adjusted based on future clinical outcomes.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 4:13 pm

GDRX

Citigroup analyst Daniel Grosslight maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $7 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:08 pm

APP

JP Morgan analyst David Karnovsky maintains a Neutral rating on AppLovin (NASDAQ:APP) and raises the price target from $21 to $36.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:08 pm

ILMN

Citigroup analyst Patrick Donnelly has maintained a 'Sell' rating on Illumina (NASDAQ:ILMN) and lowered the price target from $180 to $150.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:07 pm

HOWL

HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:03 pm